A Phase 1 interventional study of DWP16001 and Metformin IR in Healthy, sponsored by Daewoong Pharmaceutical Co. LTD.. Completed at 1 site in Korea, Republic of. Open to male participants aged 19 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-01-13.
Sponsored by Daewoong Pharmaceutical Co. LTD. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate drug-drug interaction of DWP16001 in combination with metformin IR 1000mg in Healthy male subjects.
Daewoong Pharmaceutical Co. LTD. is the lead sponsor of 200 studies on the registry; 33 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: DWP16001
Drug: Metformin IR
Drug: DWP16001+Metformin IR
Tablets, Oral, once daily single dose
Metformin IR 1000mg, Tablets, Oral, BID for 7 days
Drug pages: Enavogliflozin · Metformin
Tablets, Oral, once daily single dose DWP16001 Metformin IR 1000mg
Cmax of DWP16001
Peak Plasma Concetration
Time frame: 0-72 hours
AUClast of DWP16001
Area under the plasma concentration versus time curve
Time frame: 0-72 hours
Cmax,ss of Metformin
Peak Plasma Concetration at steady-state
Time frame: 0-144 hours
AUCτ,ss of Metformin
Area under the plasma concentration versus time curve at Tau, steady-state
Time frame: 0-144 hours
Tmax of DWP 16001, Metformin, DWP16001 Metabolites
Time at Cmax
Time frame: 0-144 hours
AUC of DWP 16001, Metformin, DWP16001 Metabolites
Area under the plasma concentration versus time curve
Time frame: 0-144 hours
T1/2 of DWP 16001, Metformin
Time frame: 0-144 hours
CL/F of DWP 16001, Metformin
Apparent total clearance of the drug from plasma after oral administration
Time frame: 0-144 hours
fe of DWP 16001, DWP16001 Metabolites
Fraction of the drug excreted into the urine
Time frame: 0-72 hours
CLR of DWP 16001
Renal clearance of the drug from plasma
Time frame: 0-144 hours
Ran from Aug 2019 to primary completion in Nov 2019, 3 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Enavogliflozin · Metformin
Daewoong Pharmaceutical Co. LTD. →